Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients
Sponsor: Tang Ziren
Summary
This study will be a single-center, prospective, randomized controlled trial with an estimated sample size of 64 patients. Eligible patients will be randomly assigned in a 1:1 ratio to receive TTM for either 24 hours or 72 hours. The primary outcome measure will be the changes in thrombin function indices at various time points during TTM treatment in both groups. The secondary endpoints of the study include additional coagulation function indicators, the incidence of bleeding-related events between the two groups, the amount of blood products used, the incidence of thrombotic events, and the CPC scores at 28 days and 6 months for both groups.
Official title: The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients (ITTC Trial): A Single-Center, Prospective, Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2024-12-01
Completion Date
2025-12-31
Last Updated
2025-04-11
Healthy Volunteers
No
Interventions
Target Temperature Management Treatment
Target Temperature Management Treatment
Locations (1)
Beijing chao-yang Hospital, Capital Medical University
Beijing, Beijing Municipality, China